Synergistic synbiotic therapies for ulcerative colitis: mechanistic insights from multi-targeted pathways in animal models.

Ulcerative colitis (UC) is a chronic inflammatory bowel disease whose complex etiology is increasingly linked to gut microbiota dysbiosis. While conventional pharmacological treatments often face limitations due to side effects, cost, and variable efficacy, synbiotics combinations of probiotics and prebiotics have emerged as a promising therapeutic strategy to restore intestinal homeostasis. This review synthesizes evidence from recent animal model studies to elucidate the multifaceted mechanisms and superior efficacy of synbiotic interventions in ameliorating colitis. We demonstrate that synbiotics, whether composed of traditional components like lactobacilli, bifidobacteria, inulin, and fructooligosaccharides, or novel formulations involving exopolysaccharides, engineered glucans, and specific fatty acid-producing consortia, consistently outperform their individual components. The therapeutic effects are mediated through a synergistic restoration of gut microbial diversity, enhanced production of protective metabolites (especially short-chain fatty acids and secondary bile acids), fortification of the intestinal barrier via upregulation of tight junction proteins, and modulation of key immune pathways, including NF-κB, MAPK, and AhR. Furthermore, we highlight the advanced strategy of microencapsulation using prebiotic wall materials to enhance probiotic viability and targeted colonic delivery. The collective evidence positions synbiotics not merely as nutritional supplements but as sophisticated, multi-targeted therapeutics. This review underscores the critical need for future research to focus on structure-function relationships, precision synbiotic formulations tailored to individual microbiota profiles, and robust human clinical trials to translate these compelling preclinical results into effective clinical management strategies for UC.